Concluding the debate around dexrazoxane
15 Nov 2017
Concluding the debate around dexrazoxane
Cardiovascular toxicities from cancer treatment
The promise of immunotherapy for elderly patients
Communicating with geriatric patients
Treating AML in patients over 70
Benefits and drawbacks of dexrazoxane
Encouraging age related reviews of three new breast cancer treatments
Improving eligibility for the elderly in clinical trails
Cancer treatment related fatigue in the elderly
Treatments for elderly head and neck cancer patients
Caring for elderly cancer patients
Editor's Choice for October 2017